CareFusion — Merger or Acquisition (November 2013)
8 slides from CareFusion's merger presentation, Nov 18, 2013
Slide 1: Acquisition of Vital Signs
Exhibit 99.2 Acquisition of Vital Signs Kieran Gallahue, Chairman & CEO Jim Hinrichs, CFO November 18, 2013 © 2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
Slide 2: Forward-Looking Statements and Use of Non-GAAP Financial Measures
Forward-Looking Statements and Use of Non-GAAP Financial Measures “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future e
Slide 3: Transaction highlights
Transaction highlights Adds scale to Procedural Solutions – Strengthens existing call points and adds anesthesia call point with scale Expands OUS footprint with direct sales channel in Europe, Middle East and Asia EPS Accretive and meets ROIC hurdle in year 3 © 2013 CareFusion Corporation or one of
Slide 4: Vital Signs at a glance
Vital Signs at a glance Overview Product Portfolio • Division of GE Healthcare Respiratory Anesthesia • ~1,000 global employees • Located in Europe, Middle East, Asia and the U.S Temperature Hemodynamics Management Geography Key Capabilities • Strong brand and legacy in the • ~$250M revenue OUS anes
Slide 5: Vital Signs Strategic Fit
Vital Signs Strategic Fit Improving the safety and cost of healthcare Medical Systems Procedural Solutions $2.33 Billion in FY13 $1.22 Billion in FY13 Infection Medical Respiratory Respiratory Dispensing Infusion Prevention Specialties Disposables Ventilators Diagnostics Infusion Skin prep Surgical
Slide 6: Investment highlights
Investment highlights Markets Building scale and margin • Becoming a leader in $3.0 billion • Adds substantial presence outside U.S. market for respiratory and • Fully integrated manufacturer vs. anesthesia consumables specialty distributor • Expanding Specialty Disposables • Adds new customer call
Slide 7: Updated Fiscal 2014 Guidance
Updated Fiscal 2014 Guidance November 18, 2013 FY14 Guidance FY14 Guidance Provided Aug 8, 2013 Updated¹ Total Revenue (constant currency) 1-4% (Organic) 4-7% Medical Systems Revenue (constant currency) 1-4% (Organic) 1-4% Procedural Solutions Revenue (constant currency) 2-4% (Organic) 11-13% ² Adju
Slide 8: Non-GAAP Reconciliations
Non-GAAP Reconciliations 1 Adjusted EPS Outlook for Fiscal Year Ending June 30, 2014: GAAP Diluted Earnings per Common Share from Continuing Operations $1.96–$2.06 Estimated charges for nonrecurring items related to restructuring and acquisition integration, net of tax (mid-point of an estimated ran